p90 Ribosomal S6 Kinase 3 and Interstitial Fibrosis
Oct 3rd, 2013 by ajphearteditor
What is RSK3 and how can it help us uncover the underlying mechanisms of hypertrophic cardiomyopathy? Associate Editor Meredith Bond leads an engaging conversation between senior author Michael Kapiloff (University of Miami) and leading expert Nikolaos Frangogiannis (Albert Einstein College of Medicine) about the exciting new study by Passariello et al. Listen as we explore the clinical implications of targeting RSK3 as a crucial pathway in the pathogenesis of fibrosis. How can we translate the understanding of the mechanisms of RSK3 and its effect on cardiomyocytes and fibroblasts to targeted drug therapies for the nearly 5 million Americans—both children and adults—afflicted with left ventricular hypertrophy every year? Listen and learn more.
Catherine L. Passariello , Marjorie Gayanilo , Michael D. Kritzer , Hrishikesh Thakur , Zoharit Cozacov , Francesca Rusconi , David Wieczorek , Michael Sanders , Jinliang Li, Michael S. Kapiloff p90 ribosomal S6 kinase 3 contributes to cardiac insufficiency in α-tropomyosin Glu180Gly transgenic mice Am J Physiol Heart Circ Physiol, published online August 2, 2013, doi: 10.1152/ajpheart.00237.2013.